Ligand id: 6823

Name: irinotecan

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: irinotecan

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 112.51
Molecular weight 586.28
XLogP 4.12
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

1. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR. (2004)
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
J. Mol. Biol., 339 (4): 773-84. [PMID:15165849]
2. Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. (1998)
Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
J. Pharmacol. Exp. Ther., 286 (1): 578-83. [PMID:9655905]
3. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. (1987)
Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
Cancer Res., 47 (22): 5944-7. [PMID:3664496]
4. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T. (1988)
Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.
Cancer Chemother. Pharmacol., 21 (4): 308-12. [PMID:3370738]
5. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, Antony S, Meng L, Liao Z, Kohlhagen G et al.. (2003)
Repair of and checkpoint response to topoisomerase I-mediated DNA damage.
Mutat. Res., 532 (1-2): 173-203. [PMID:14643436]
6. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin Jr AB, Stewart L. (2002)
The mechanism of topoisomerase I poisoning by a camptothecin analog.
Proc. Natl. Acad. Sci. U.S.A., 99 (24): 15387-92. [PMID:12426403]
7. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. (1994)
Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
J. Natl. Cancer Inst., 86 (11): 836-42. [PMID:8182764]
8. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. (1988)
Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
Cancer Chemother. Pharmacol., 21 (1): 71-4. [PMID:3342468]